KALA
KALA BIO, Inc.
- PER (TTM)
- -
- PER (Forward)
- -0.01
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 0.32
- 시가총액
- 1.47M
- 배당수익률
- -
- 베타
- -2.24
- 1개월 수익률
- -56.83%
- 3개월 수익률
- -82.05%
- 6개월 수익률
- -89.64%
- 1년 수익률
- -97.71%
- 2년 수익률
- -
- 5일 평균거래량
- 82686
- 60일 평균거래량
- 161109
- 1년 평균거래량
- 84369
- 5d/60d 거래량 비율
- 0.51×
- 60d/1y 거래량 비율
- 1.91×
- 변동성(60일, 연환산)
- 132.17%
- BB 스퀴즈 스코어
- 1.34
- SMA50 비율
- 0.38
- SMA200 비율
- 0.03
- RSI (14)
- 24
- 20일 수렴도
- 0.32
- 52주 최고
- 981.50
- 52주 최저
- 3.95
- 고점 대비
- -99.60%
- 저점 대비
- 0.00%
펀더멘털 갱신: 2026-05-10T09:41:56+00:00 · 시세 갱신: 2026-05-10T06:45:54+00:00
회사 정보
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.